We are live on ! Find out more
ACRV icon

Acrivon Therapeutics
ACRV

44 hedge funds and large institutions have $22.6M invested in Acrivon Therapeutics in 2026 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 11 increasing their positions, 11 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 11

8% less funds holding

Funds holding: 48 → 44 (-4)

17.07% less ownership

Funds ownership: 58.98% → 41.91% (-17%)

23% less first-time investments, than exits

New positions opened: 10 | Existing positions closed: 13

50% less capital invested

Capital invested by funds: $44.9M → $22.6M (-$22.3M)

Holders
44
Holders Change
-4
Holders Change %
-8.33%
% of All Funds
0.54%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
10
Increased
11
Reduced
11
Closed
13
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$462K
2
GCP
GSA Capital Partners
United Kingdom
+$326K
3
Renaissance Technologies
Renaissance Technologies
New York
+$217K
4
BCM
Bridgeway Capital Management
Texas
+$202K
5
Marshall Wace
Marshall Wace
United Kingdom
+$112K

Top Sellers

1
Citadel Advisors
Citadel Advisors
Florida
-$3.96M
2
ACA
Acorn Capital Advisors
New York
-$977K
3
UBS Group
UBS Group
Switzerland
-$548K
4
Two Sigma Investments
Two Sigma Investments
New York
-$341K
5
Millennium Management
Millennium Management
New York
-$293K
Name Holding Trade Value Shares
Change 		Change in
Stake
Goldman Sachs
26
Goldman Sachs
New York
$20.5K -$183K -104,680 -88%
TSS
27
Two Sigma Securities
New York
$16.2K +$20.4K +11,679 New
AWM
28
AAF Wealth Management
Massachusetts
$14.8K – – –
Fidelity Investments
29
Fidelity Investments
Massachusetts
$13.1K +$1.4K +800 +9%
Federated Hermes
30
Federated Hermes
Pennsylvania
$11K +$4.03K +2,312 +41%
Barclays
31
Barclays
United Kingdom
$8.26K -$32.2K -18,462 -76%
TRCT
32
Tower Research Capital (TRC)
New York
$6.29K +$7.89K +4,526 New
VGA
33
Vanguard Global Advisers
Pennsylvania
$6.19K +$7.77K +4,453 New
Wells Fargo
34
Wells Fargo
California
$4.17K +$5.23K +3,000 New
BNP Paribas Financial Markets
35
BNP Paribas Financial Markets
France
$881 – – –
JP Morgan Chase
36
JP Morgan Chase
New York
$823 -$28.3K -16,226 -96%
Nisa Investment Advisors
37
Nisa Investment Advisors
Missouri
$812 – – –
RPA
38
Redwood Park Advisors
California
$695 – – –
Russell Investments Group
39
Russell Investments Group
United Kingdom
$669 – – –
FDCDDQ
40
Federation des caisses Desjardins du Quebec
Quebec, Canada
$556 – – –
SPIA
41
Steward Partners Investment Advisory
New York
$453 +$569 +326 New
SS
42
SBI Securities
Japan
$103 – – –
CIAM
43
Caitong International Asset Management
Hong Kong
$6 +$7 +4 New
Citadel Advisors
44
Citadel Advisors
Florida
– -$3.96M -1,641,884 Closed
ACA
45
Acorn Capital Advisors
New York
– -$977K -405,237 Closed
Two Sigma Advisers
46
Two Sigma Advisers
New York
– -$804K -333,773 Closed
Millennium Management
47
Millennium Management
New York
– -$293K -121,524 Closed
BBA
48
Baker Bros. Advisors
New York
– -$55K -22,809 Closed
QC
49
Quadrature Capital
United Kingdom
– -$50K -20,730 Closed
VWWMG
50
Vermillion & White Wealth Management Group
Pennsylvania
– -$43.6K -18,100 Closed
1
2
3

ACRV Hedge Fund Activity: Q1 2026 in Review

44 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Acrivon Therapeutics (ACRV) for Q1 2026, worth a combined $22.6M — down 50% from $44.9M a quarter earlier.

Sellers outnumbered buyers: 13 funds closed out of ACRV and 10 opened new positions — a net loss of 3 holders — while 11 trimmed existing stakes and 11 added.

The largest buyer was Acadian Asset Management, adding an estimated $462K. The largest seller was Citadel Advisors, exiting entirely with an estimated $3.96M sold.

  • 44 institutional investors held Acrivon Therapeutics (ACRV) as of Q1 2026, down from 48 in Q4 2025.
  • Funds reported $22.6M of Acrivon Therapeutics stock for Q1 2026, down 50% quarter-over-quarter.
  • 10 funds opened new Acrivon Therapeutics positions in Q1 2026 and 13 closed out, a net change of -3 holders.
  • The largest Acrivon Therapeutics buyer in Q1 2026 was Acadian Asset Management, an estimated $462K added.
  • The largest Acrivon Therapeutics seller in Q1 2026 was Citadel Advisors, an estimated $3.96M sold.

Based on aggregated 13F filings for Q1 2026.